Ivermectin and hydroxychloroquine are sometimes mentioned in the same breath because both became household names during the COVID-19 pandemic. But outside that shared moment of public attention, they have almost nothing in common. They come from different chemical families, were developed for entirely different diseases, act on the body through different biological pathways, and carry different safety profiles. This article lays out what each drug actually is, what it is approved to treat, what the evidence does and does not show about repurposed uses, and what is known — and not known — about taking them together.

Two Different Origins, Two Different Chemistries

Ivermectin belongs to a class of compounds called avermectins, derived from a soil-dwelling bacterium, Streptomyces avermitilis. It was isolated in the 1970s through research led by Satoshi Ōmura in Japan, with further development by William Campbell at Merck, work recognized with the 2015 Nobel Prize in Physiology or Medicine. It is a fair example of the created world yielding remedies from unlikely places — a humble organism in ordinary soil, put to extraordinary use against parasitic disease that has afflicted millions of the world's poorest people.

Hydroxychloroquine is a synthetic derivative of chloroquine, which in turn traces its lineage to quinine, a compound extracted from the bark of the South American Cinchona tree. Indigenous populations and later European physicians used Cinchona bark for fevers long before the active compound was isolated in the 19th century. Hydroxychloroquine itself was developed in the mid-20th century as a less toxic alternative to chloroquine for long-term use.

How Each Drug Actually Works

Ivermectin's primary mechanism is neuromuscular. It binds selectively to glutamate-gated chloride channels found in the nerve and muscle cells of invertebrates — parasitic worms and arthropods such as mites and lice. This binding causes an influx of chloride ions, leading to paralysis and death of the parasite. It also has some affinity for GABA-gated chloride channels. Mammals have GABA-gated channels too, but they are concentrated in the central nervous system, which is normally shielded by the blood-brain barrier, and mammalian glutamate-gated chloride channels have much lower affinity for the drug than invertebrate versions. This is the pharmacological reason ivermectin can kill a parasite without meaningfully affecting the human nervous system at standard doses.

Hydroxychloroquine works completely differently and has two distinct modes of action depending on the condition being treated. Against the malaria parasite Plasmodium, it accumulates in the parasite's digestive vacuole, raises the internal pH, and interferes with the parasite's ability to detoxify heme released from digested hemoglobin — a process toxic to the parasite itself. In autoimmune disease, its relevant mechanism is different: it accumulates in immune cells' lysosomes, interferes with toll-like receptor signaling, and dampens the antigen presentation and cytokine release that drive inflammation in conditions such as lupus and rheumatoid arthritis. In short, ivermectin is a neuromuscular poison aimed at parasites, and hydroxychloroquine is a pH-altering, immune-modulating compound aimed at either a protozoan parasite or the body's own overactive immune response.

What Each Drug Is Actually Approved to Treat

Ivermectin, taken orally, is approved for infections including:

It has a decades-long record of use in global mass drug administration programs and is generally well tolerated, with dizziness, nausea, and diarrhea being the most common complaints.

Hydroxychloroquine is approved for:

It requires more monitoring than ivermectin during long-term use, particularly periodic eye exams, because cumulative exposure carries a risk of retinal toxicity. It can also prolong the QT interval on an electrocardiogram, which matters for patients with existing heart rhythm issues or those on other QT-prolonging medications.

Neither drug is approved anywhere in the world specifically for the treatment or prevention of COVID-19, and that fact is worth stating plainly rather than leaving implied.

Why Both Were Tested Against COVID-19, and What the Evidence Showed

Early in the pandemic, laboratory studies gave both drugs a plausible reason for interest. A widely cited in vitro study from Monash University in Australia (2020) found that ivermectin reduced SARS-CoV-2 replication in cell culture, but the concentrations required were far higher than what is achievable in humans at approved doses. Chloroquine and hydroxychloroquine had likewise shown antiviral activity against SARS-CoV-2 in cell culture, and a small, non-randomized French study out of Marseille (Raoult and colleagues, early 2020) reported viral clearance with hydroxychloroquine, sometimes combined with azithromycin. That study drew substantial criticism for its size and design, and it should be read as preliminary and exploratory, not confirmatory.

Both drugs were then tested in much larger, better-designed human trials, and the results diverged from the early laboratory promise:

Taken together, the pattern for both drugs is the same: encouraging signals in a test tube did not translate into benefit in properly randomized human trials at safe doses. That is not an unusual outcome in medicine — many compounds that inhibit a virus in a petri dish fail once dosing, absorption, and human physiology are accounted for — and it is why regulatory bodies including the FDA, EMA, and WHO do not recommend either drug for COVID-19 outside of a clinical trial setting. Readers deserve that conclusion stated clearly rather than left ambiguous, because clear information is part of respecting a patient's ability to make an informed decision with their own physician.

Safety Profiles, Interactions, and Whether They Can Be Combined

There is no approved medical indication for which ivermectin and hydroxychloroquine are prescribed together. Because they treat different diseases through different mechanisms, a physician would have no standard clinical reason to combine them, and the combination has not been formally studied for safety or efficacy as a pair.

That said, some general pharmacological points are worth knowing:

The responsible position is straightforward: taking either drug — let alone both — without a diagnosed indication and a physician's direct involvement is not something this article can responsibly encourage, and self-directed combination use is where risk is least understood. Anyone taking hydroxychloroquine for lupus or rheumatoid arthritis who is prescribed ivermectin for a parasitic infection should simply tell their physician about both medications, as they would with any prescription, so that liver function and cardiac risk factors can be reviewed appropriately.

Making Sense of the Choice Between Them

"Ivermectin or hydroxychloroquine" is, in truth, rarely a real clinical decision, because the two drugs are not interchangeable for the same problem. A patient with river blindness or strongyloidiasis needs ivermectin; a patient with lupus needs hydroxychloroquine; a patient with malaria may need either chloroquine-class drugs or an entirely different antimalarial depending on regional resistance patterns. The apparent rivalry between the two names is a product of pandemic-era public debate, not of any genuine overlap in what these medicines are for.

What both stories do illustrate is worth holding onto: these are two medicines with real, well-documented value for the diseases they were designed to treat, discovered through patient scientific work and, in ivermectin's case, from a compound found in ordinary soil — a reminder that the created world still yields remedies to those who look for them. Good stewardship of one's own health means understanding a medicine's actual approved purpose, discussing new or repurposed uses honestly with a trusted physician, and resisting both blanket dismissal and uncritical enthusiasm. Informed consent works both ways: a patient is entitled to know what a drug is proven to do, what it is not proven to do, and what remains genuinely uncertain.